Nabil Chehab

3.7k total citations · 3 hit papers
17 papers, 3.0k citations indexed

About

Nabil Chehab is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nabil Chehab has authored 17 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nabil Chehab's work include Cancer-related Molecular Pathways (10 papers), Epigenetics and DNA Methylation (5 papers) and DNA Repair Mechanisms (4 papers). Nabil Chehab is often cited by papers focused on Cancer-related Molecular Pathways (10 papers), Epigenetics and DNA Methylation (5 papers) and DNA Repair Mechanisms (4 papers). Nabil Chehab collaborates with scholars based in United States, Russia and Canada. Nabil Chehab's co-authors include Thanos D. Halazonetis, Asra Malikzay, Linda Schultz, Michael Appel, Elena S. Stavridi, Shelley L. Berger, Nickolai A. Barlev, Kyle D. Mansfield, Lin Liu and Nikola P. Pavletich and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Nabil Chehab

17 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

P53 Binding Protein 1 (53bp1) Is an Early Participant in the Cellular Response to DNA Double-Strand Breaks

2000 734 citations Linda Schultz, Nabil Chehab et al. The Journal of Cell Biology profile →
Chk2/hCds1 functions as a DNA damage checkpoint in G₁by stabilizing p53

2000 653 citations Nabil Chehab, Asra Malikzay et al. Genes & Development profile →
Acetylation of p53 Activates Transcription through Recruitment of Coactivators/Histone Acetyltransferases

2001 590 citations Nickolai A. Barlev, Lin Liu et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nabil Chehab United States	14	2.5k	1.6k	517	354	235	17	3.0k
Andrew C. Phillips United States	18	2.1k 0.8×	1.7k 1.1×	378 0.7×	270 0.8×	166 0.7×	29	2.7k
Carl G. Maki United States	27	2.3k 0.9×	1.8k 1.1×	584 1.1×	328 0.9×	154 0.7×	62	2.9k
David Dornan United States	20	2.5k 1.0×	1.4k 0.9×	816 1.6×	281 0.8×	168 0.7×	38	3.1k
Jack T. Zilfou United States	15	2.1k 0.8×	1.1k 0.7×	485 0.9×	208 0.6×	314 1.3×	19	2.7k
Asra Malikzay United States	10	1.7k 0.7×	1.1k 0.7×	398 0.8×	305 0.9×	135 0.6×	11	2.1k
Kuniyoshi Iwabuchi Japan	22	2.5k 1.0×	1.1k 0.7×	593 1.1×	311 0.9×	142 0.6×	40	2.9k
Lyubomir T. Vassilev United States	22	2.1k 0.8×	1.4k 0.9×	328 0.6×	596 1.7×	130 0.6×	37	2.8k
Gareth L. Bond United Kingdom	23	2.6k 1.1×	2.2k 1.3×	825 1.6×	278 0.8×	277 1.2×	41	3.6k
Franck Toledo France	22	2.5k 1.0×	1.6k 1.0×	594 1.1×	241 0.7×	530 2.3×	45	3.2k
Hidehiko Kawai Japan	28	2.0k 0.8×	1.5k 0.9×	430 0.8×	780 2.2×	100 0.4×	61	2.7k

Countries citing papers authored by Nabil Chehab

Since Specialization

Citations

This map shows the geographic impact of Nabil Chehab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nabil Chehab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nabil Chehab more than expected).

Fields of papers citing papers by Nabil Chehab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nabil Chehab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nabil Chehab. The network helps show where Nabil Chehab may publish in the future.

Co-authorship network of co-authors of Nabil Chehab

This figure shows the co-authorship network connecting the top 25 collaborators of Nabil Chehab. A scholar is included among the top collaborators of Nabil Chehab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nabil Chehab. Nabil Chehab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Chiang, Anne C., Ancilla W. Fernandes, Melissa Pavilack, et al.. (2020). EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer. 20(1). 356–356. 23 indexed citations

Bridges, John F. P., Melissa Pavilack, Emuella Flood, et al.. (2019). Patient Preferences for Attributes of Tyrosine Kinase Inhibitor Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer. Future Oncology. 15(34). 3895–3907. 13 indexed citations

Chiang, Anne C., Melissa Pavilack, François Laliberté, et al.. (2018). MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs. Journal of Thoracic Oncology. 13(10). S410–S411. 14 indexed citations

Gray, Jhanelle E., Bharat Thakrar, Ping‐Hui Sun, et al.. (2018). Treatment (tx) patterns in patients (pts) with lung cancer starting 1st or 2nd generation (1G/2G) EGFR-TKI: A US insurance claims database analysis. Annals of Oncology. 29. ix156–ix157. 6 indexed citations

Yin, Yongjun, Craig S. Smith, Qianxu Guo, et al.. (2016). Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody. Disease Models & Mechanisms. 9(5). 563–571. 15 indexed citations

Rosenberg, Jonathan E., Lillian Werner, Aristotelis Bamias, et al.. (2012). FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.. Journal of Clinical Oncology. 30(15_suppl). 4577–4577. 2 indexed citations

Cai, Zhenjian, Nabil Chehab, & Nikola P. Pavletich. (2009). Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase. Molecular Cell. 35(6). 818–829. 131 indexed citations

Barlev, Nickolai A., Lin Liu, Nabil Chehab, et al.. (2001). Acetylation of p53 Activates Transcription through Recruitment of Coactivators/Histone Acetyltransferases. Molecular Cell. 8(6). 1243–1254. 590 indexed citations breakdown →

Stavridi, Elena S., Nabil Chehab, Asra Malikzay, & Thanos D. Halazonetis. (2001). Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest.. PubMed. 61(19). 7030–3. 44 indexed citations

10.

Schultz, Linda, Nabil Chehab, Asra Malikzay, et al.. (2000). The DNA Damage Checkpoint and Human Cancer. Cold Spring Harbor Symposia on Quantitative Biology. 65(0). 489–498. 18 indexed citations

11.

Chehab, Nabil, Asra Malikzay, Michael Appel, & Thanos D. Halazonetis. (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G₁by stabilizing p53. Genes & Development. 14(3). 278–288. 653 indexed citations breakdown →

12.

Schultz, Linda, Nabil Chehab, Asra Malikzay, & Thanos D. Halazonetis. (2000). P53 Binding Protein 1 (53bp1) Is an Early Participant in the Cellular Response to DNA Double-Strand Breaks. The Journal of Cell Biology. 151(7). 1381–1390. 734 indexed citations breakdown →

13.

Satyamoorthy, Kapaettu, Nabil Chehab, Matthew J.F. Waterman, et al.. (2000). Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.. PubMed. 11(9). 467–74. 78 indexed citations

14.

Stavridi, Elena S., et al.. (1999). Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions. Protein Science. 8(9). 1773–1779. 12 indexed citations

15.

Chehab, Nabil, Asra Malikzay, Elena S. Stavridi, & Thanos D. Halazonetis. (1999). Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proceedings of the National Academy of Sciences. 96(24). 13777–13782. 463 indexed citations

16.

Chehab, Nabil, et al.. (1998). Glutamine Substitution at Alanine1649 in the S4–S5 Cytoplasmic Loop of Domain 4 Removes the Voltage Sensitivity of Fast Inactivation in the Human Heart Sodium Channel. The Journal of General Physiology. 111(5). 639–652. 21 indexed citations

17.

Scolnick, Daniel M., Nabil Chehab, Elena S. Stavridi, et al.. (1997). CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein.. PubMed. 57(17). 3693–6. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact